Cervical intraepithelial neoplasia

Cervical Intraepithelial Neoplasia, Pipeline Review, H2 2019 - Bioleaders Corp, Elicio Therapeutics, Novan Inc & Vaccibody AS - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 14, 2020
Health, Pharmaceutical, Infectious causes of cancer, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Gynaecological cancer, Health, Clinical medicine, Medicine, Papillomavirus, Vaccines

The "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.

ASKA Pharmaceutical Co., Ltd. and KinoPharma, Inc. Enter into Option Agreement for Treatment of Cervical Dysplasia

Retrieved on: 
Tuesday, January 14, 2020
Cancer, Infectious causes of cancer, RTT, Papillomavirus, Gynaecological cancer, Women's health, Cervical intraepithelial neoplasia, Cervical cancer, Human papillomavirus infection, Cervix, Preterm birth, HPV vaccine

Cervical dysplasia is a preliminary stage of cervical cancer, and its causes are predominantly due to persistent infections of human papillomaviruses (HPV) in the cervix.

Key Points: 
  • Cervical dysplasia is a preliminary stage of cervical cancer, and its causes are predominantly due to persistent infections of human papillomaviruses (HPV) in the cervix.
  • Excision surgery is the first choice for high-grade cervical dysplasia, but it has been reported that the surgery increases the risk of premature delivery.
  • At present, there is no medication for treating HPV in case of the low- and moderate-grade cervical dysplasia.
  • Established in April 2005, KinoPharma is a pharmaceutical company engaged in research and development of drugs in collaboration with Kyoto University.

PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019

Retrieved on: 
Monday, November 25, 2019
Medical specialties, Medicine, Branches of biology, Immune system, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cancer immunotherapy, T cell

Details for the presentation are below:

Key Points: 
  • Details for the presentation are below:
    The Versamune platform is PDS Biotechs proprietary, synthetic lipid-based T-cell activating platform, which works by facilitating several critical immunological pathways.
  • The strong T-cell induction also resulted in complete regression of lesions in the majority of treated cervical intraepithelial neoplasia (CIN) patients.
  • PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform.
  • Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors.

Global HPV Testing & PAP Test Market Analysis Report, 2019-2024 - Key Players are Abbott Laboratories, Qiagen, Becton, Dickinson & Company, and Roche - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 6, 2019
Medical devices, Health, Cancer, Infectious causes of cancer, Gynaecological cancer, RTT, Papillomavirus, Sexually transmitted diseases and infections, Human papillomavirus infection, Pap test, Cervical cancer, Qiagen, Cervical screening, Cervical intraepithelial neoplasia

The "HPV Testing & PAP Test Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing & PAP Test Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • Therefore the increasing number of cases of cervical cancer has boosted the demand for HPV testing and PAP testing market.
  • Thus the increasing number of cervical cancer cases has boosted the demand for HPV testing and Pap testing market.
  • Some key players in the HPV test and Pap test market include Abbott Laboratories, Qiagen, Becton, Dickinson and Company, Roche and many others.

PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data

Retrieved on: 
Tuesday, October 1, 2019
Cancer, Infectious causes of cancer, Papillomavirus, RTT, Vaccines, Cervical intraepithelial neoplasia, Human papillomavirus infection, Intraepithelial neoplasia, Cervarix, HspE7

BERKELEY HEIGHTS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional immunotherapeutic products, today announced it will prioritize clinical development of PDS0101 in advanced cancers following its recent reporting of promising PDS0101 Phase 1 clinical trial outcome data.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional immunotherapeutic products, today announced it will prioritize clinical development of PDS0101 in advanced cancers following its recent reporting of promising PDS0101 Phase 1 clinical trial outcome data.
  • On September 19, 2019, PDS reported clinical outcome data from a Phase 1 clinical trial of PDS0101 in patients with cervical intraepithelial neoplasia (CIN) infected with multiple high-risk, cancer-causing types of human papillomavirus (HPV).
  • Our intent is to continue to advance our previously announced combination studies with PDS0101 in various advanced HPV-associated cancers.
  • This approach has been recently supported by promising Phase 1 clinical outcome data, said Dr. Frank Bedu-Addo, CEO of PDS.

Novan Awarded Approximately $1.1 Million Grant by Department of Defense

Retrieved on: 
Friday, September 20, 2019
Infectious causes of cancer, Health, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, National Institutes of Health, Articles, Vaccines

The grant will support the development of a product candidate (WH504) for the treatment of cervical intraepithelial neoplasia (CIN), with well-characterized physical chemical properties suitable for intravaginal administration.

Key Points: 
  • The grant will support the development of a product candidate (WH504) for the treatment of cervical intraepithelial neoplasia (CIN), with well-characterized physical chemical properties suitable for intravaginal administration.
  • This grant is in addition to the previously announced National Institute of Health (NIH) Phase 1 grant of approximately $223,000 for the development of a separate product candidate (WH602).
  • Both product candidates will represent core initiatives within the previously announced Novan womens health business unit.
  • The views expressed in this press release are those of the Company and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

Novan Advances Women’s Health Business Unit with Non-Dilutive Funding

Retrieved on: 
Wednesday, August 14, 2019
Infectious causes of cancer, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Health, Clinical medicine

These grants will provide funding on a non-dilutive basis for specific initiatives within product advancement for the treatment of cervical intraepithelial neoplasia (CIN).

Key Points: 
  • These grants will provide funding on a non-dilutive basis for specific initiatives within product advancement for the treatment of cervical intraepithelial neoplasia (CIN).
  • Prospectively, Novan expects to be eligible to receive additional grant dollars for Phase 2 and 3 extensions.
  • Both product candidates will represent the core to Novans womens health business unit.
  • This unit will continue to be supported through a collaboration with Health Decisions, Inc. (Health Decisions).

US Cervical Dysplasia Market and Competitive Landscape, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 5, 2019
Pharmaceutical, Health, Oncology, Infectious causes of cancer, Oncology, Histopathology, Medicine, Medical specialties, Dysplasia, Health, Cervical intraepithelial neoplasia, RTT

The "US Cervical Dysplasia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Cervical Dysplasia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • The latest research, US Cervical Dysplasia Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Cervical Dysplasia pipeline products, Cervical Dysplasia epidemiology, Cervical Dysplasia market valuations and forecast, Cervical Dysplasia drugs sales and competitive landscape in the US.
  • Cervical Dysplasia pipeline: Find out the products in clinical trials for the treatment of Cervical Dysplasia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Cervical Dysplasia drugs: Identify key products marketed and prescribed for Cervical Dysplasia in the US, including trade name, molecule name, and company
    Cervical Dysplasia market valuations: Find out the market size for Cervical Dysplasia drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Cervical Dysplasia drugs market share: Find out the market shares for key Cervical Dysplasia drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Cervical Dysplasia products

Cervical Dysplasia Clinical Trial Pipeline Highlights 2019 - Track Competition, Identify Partners, Formulate Business Development Strategies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 12, 2019
Women, Health, Clinical trials, Pharmaceutical, Consumer, Health, Medicine, Infectious causes of cancer, Drug discovery, Clinical research, Design of experiments, Cervical intraepithelial neoplasia, Clinical trial, Dysplasia, HspE7

The "Global Cervical Dysplasia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cervical Dysplasia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Cervical Dysplasia Pipeline Highlights - 2019 provides most up-to-date information on key pipeline products in the global Cervical Dysplasia market.
  • It covers emerging therapies for Cervical Dysplasia in active clinical development stages including early and late stage clinical trials.
  • The report provides Cervical Dysplasia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Transgene: Peer-Reviewed Publications Confirm the Potential of Transgene’s TG4001 and TG6002

Retrieved on: 
Wednesday, June 5, 2019
Health, Biotechnology, Clinical trials, Infectious diseases, Oncology, Pharmaceutical, Other Health, Cancer, Medicine, Infectious causes of cancer, Papillomavirus, RTT, Vaccines, Gynaecological cancer, Cervical intraepithelial neoplasia, Human papillomavirus infection, Intraepithelial neoplasia, Precancerous condition, Oncolytic virus

The data confirm the potential of TG4001 (Tipapkinogen Sovacivec), administered as a monotherapy, to treat precancerous HPV-induced lesions (cervical intraepithelial neoplasia - CIN2/3).

Key Points: 
  • The data confirm the potential of TG4001 (Tipapkinogen Sovacivec), administered as a monotherapy, to treat precancerous HPV-induced lesions (cervical intraepithelial neoplasia - CIN2/3).
  • Irrespective of baseline HPV infection, viral DNA clearance2 was higher in the vaccine group compared to placebo (p
  • TG4001 was well tolerated with the most common adverse events being injection site reactions.
  • Harper, et al., Gynecologic Oncology -
    Transgene provides detailed preclinical data on its oncolytic virus TG6002.